Translational Cancer Research
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
TCR is an international peer-reviewed journal, published by AME Publishing Company. It is published bimonthly (Jun. 2012 - Aug. 2019), monthly (Sep. 2019 - ) and openly distributed worldwide.
Essential Science Indicators Field
Review policy on Publons
- Does not allow reviews to be publicly displayed
- Only allows reviewers to display the journal they reviewed for
Interested in reviewing for this journal?
We can put registered members of Publons' reviewer community in touch with partnered journals they would like to review for. Register now to let Translational Cancer Research know you want to review for them.
Editorial board members on Publons
Publons users have indicated that they sit on Translational Cancer Research's editorial board but we are unable to verify these claims.